Patent Assignment
Reel/Frame 024380/0645
Security Agreement
Recorded: 2010-05-14
Pages: 9
Assignor
KING PHARMACEUTICALS, INC.
Executed: 2010-05-11
Assignee
CREDIT SUISSE AG
AS ADMINSTRATIVE AGENT, 11 MADISON AVENUE, NEW YORK, NEW YORK, 10011
Covered Properties
(27)
Beta-Lactam Antibiotics
Patent:
5,142,039 →
Application:
07/588,381 →
Enantiomerically Selective Biocatalyzed Acylation
Patent:
5,057,607 →
Application:
07/591,586 →
Process for Preparing 4-Substituted Azetidinones
Patent:
5,106,475 →
Application:
07/598,527 →
3-Thiazolylthio Carbacephem Antibacterial Agents
Patent:
5,077,287 →
Application:
07/643,244 →
Ring-Closure Method for 1-Carbacephalosporin Six-Membered Ring
Patent:
5,089,610 →
Application:
07/691,257 →
Process of Enantiomeric Separation of Carbacephem Intermediates
Patent:
5,142,038 →
Application:
07/734,394 →
Intermediates to 1-Carbacephalosporins and Process for Preparation Thereof
Patent:
5,159,073 →
Application:
07/735,747 →
Novel 4-(2,3 Epoxy Propane) Azetidinones
Patent:
5,116,972 →
Application:
07/744,857 →
New Amino Protecting Group
Patent:
5,169,945 →
Application:
07/750,214 →
Pharmaceutical Composition
Patent:
5,248,493 →
Application:
07/771,795 →
Bicyclic Beta-Lactam Antibiotics
Patent:
5,239,068 →
Application:
07/871,376 →
Process and Intermediates for Chiral Epoxides
Patent:
5,256,807 →
Application:
07/881,913 →
Intermediates to 1-Carbacephalosporins and Process for Preparation Thereof
Patent:
5,225,553 →
Application:
07/889,221 →
New Amino Protecting Group
Patent:
5,239,069 →
Application:
07/918,196 →
Process and Intermediates for Chiral Epoxides
Patent:
5,296,615 →
Application:
08/012,109 →
Amino Protecting Group
Patent:
5,283,329 →
Application:
08/025,301 →
Process for Converting Loracarbef Dihydrate to Loracarbef Monohydrate
Patent:
5,374,719 →
Application:
08/071,550 →
Process for Preparing Crystalline Beta-Lactam Monohydrate
Patent:
5,352,782 →
Application:
08/071,552 →
Loracarbef Isopropanolate and a Process for Converting Loracarbef Isopropanolate to Loracarbef Monohydrate
Patent:
5,399,686 →
Application:
08/072,204 →
Loracarbef Hydrochloride C1-C3 Alcohol Solvates and Uses Thereof
Patent:
5,550,231 →
Application:
08/077,305 →
Pharmaceutical Compositions
Patent:
5,443,833 →
Application:
08/082,804 →
Azetidinone Intermediates to Carbacephalosporins and Process
Patent:
5,453,503 →
Application:
08/104,383 →
Process for Preparing Loracarbef Monohydrate
Patent:
5,580,977 →
Application:
08/396,948 →
Loracarbef Hydrochloride C1-C3 Alcohol Solvates and Uses Thereof
Patent:
5,578,720 →
Application:
08/444,124 →
Pharmaceutical Compositions
Patent:
38,628 →
Application:
08/916,578 →
Thrombin Purification
Application:
11/927,918 →
Publication:
US 2008/0280343
Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
Application:
12/455,571 →
Publication:
US 2009/0297566
Related Assignments
(9)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 19, 2001
From: KING PHARMACEUTICALS, INC.
To: CREDIT SUISSE FIRST BOSTON
Reel/Frame 012350/0860 →
Assignment of Assignor's Interest
Mar 5, 2004
From: FISONS LIMITED
To: KING PHARMACEUTICALS INC.
Reel/Frame 015035/0592 →
Assignment of Assignor's Interest
Mar 5, 2004
From: FISONS LIMITED
To: KING PHARMACEUTICALS, INC.
Reel/Frame 015102/0943 →
Assignment of Assignor's Interest
Mar 5, 2004
From: FISONS LIMITED
To: KING PHARMACEUTICALS, INC.
Reel/Frame 015035/0600 →
Security Agreement
Dec 30, 2008
From: KING PHARMACEUTICALS, INC.
To: CREDIT SUISSE, AS AGENT
Reel/Frame 022034/0883 →
Release of Security Interest
May 11, 2010
From: KING PHARMACEUTICALS, INC.
To: CREDIT SUISSE AG
Reel/Frame 024369/0074 →
Release of Security Interest
Feb 2, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS, INC.
Reel/Frame 025735/0513 →
Release of Security Interest
Feb 3, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS, INC.
Reel/Frame 025737/0990 →
Release of Security Interest
Feb 4, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS, INC.
Reel/Frame 025746/0793 →